Natera (NASDAQ:NTRA) Stock

Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

Billionaire investor Stanley Druckenmiller&#39;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4

Jim Cramer and GameStop

Large Cap

Short Sellers

Movers

Trading Ideas

BMRN

BNTX

FTAI

ICLR

MRNA

RGTI

RKLB

SNAP

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

60-40-

Personal Finance

AMSC

DELL

POWL

Since bonds don&#39;t protect against stock declines, it&#39;s time for a different approach. 

The End Of The 60/40 Portfolio

Natera Inc

Billionaire investor Stanley Druckenmiller&#8216;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
What Happened: According to a recent&nbsp;SEC filing, Druckenmiller, a seasoned investor, sold all his shares of&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) in the fourth quarter. This move comes on the heels of his total exit from Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a competing chipmaker, a few months prior.
In the closing months of 2024, Druckenmiller significantly reduced his tech stock portfolio, selling his entire stakes in&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Adobe Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) and&nbsp;Autodesk Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>). He also completely sold his stake in&nbsp;Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) and his shares in insurance company&nbsp;Chubb Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
Despite these divestments, Druckenmiller increased his investments in several big tech companies in the same quarter, acquiring new positions in&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Elon Musk&#8216;s electric vehicle manufacturer&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Druckenmiller&#8217;s Duquesne also initiated new investments in United Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Warner Bros. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
The most significant holding in his Duquesne Family Office remains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), the clinical genetic-testing company in which they held a stake since 2022. Natera holdings account for just over 15% of the portfolio. Meanwhile, the firm increased its stake in Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) by nearly 6.3 times. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43649046/warner-bros-jinjiang-international-collaborate-for-harry-potter-studio-tour-in-shanghai">Warner Bros Announces Shanghai Harry Potter Studio Tour—Set To Be Four Times Larger Than London&#8217;s</a>
Why It Matters: Druckenmiller, who formerly managed hedge funds for George Soros, now manages his own wealth through the Duquesne Family Office, which has investments worth nearly $3.72 billion.
The billionaire investor&#8217;s latest moves follow his earlier divestments in AI stocks. During the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">Druckenmiller sold all of its Nvidia shares and significantly reduced its Palantir holdings</a> by 95%. This occurred despite Nvidia and Palantir experiencing significant stock surges that year, with Nvidia&#8217;s stock increasing nearly 190% and Palantir&#8217;s shares gaining over 386%. 
The current quarter&#8217;s exit from Broadcom despite the stock surging more than 100% over the past year appears as a profit booking move. Meanwhile, other additions in big tech stocks show his growing confidence in the sector.
Druckenmiller added Tesla to its portfolio which surged over 83% in the past year. However, the stock plunged more than 16% over the last month, amid declining global sales, regulatory roadblocks in China, earnings disappointment, and Musk&#8217;s increasing political involvement. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 23.29% on an annualized basis producing an average annual return of 36.12%. Currently, Natera has a market capitalization of $23.24 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $457.37 today based on a price of $176.00 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739833208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Analyst Ratings

CDNA

VRTX

Live On CNBC, Amy Raskin Announces Trimmed Vertex Pharmaceuticals ; Trimmed Kadant Position; Trimmed Natera Position; Bought CareDx

In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents a significant step forward as it's the first time the committee has formally recognized ctDNA as being prognostic. The guidelines remain cautious about ctDNA for surveillance, as expected. The NCCN finalized these updates before data from the phase III CALGB (Alliance) / SWOG 80702 study were presented at ASCO GI in January, supporting the predictive nature of Signatera in the adjuvant setting.

Health Care

Natera Commented On Recent Updates By The NCCN On Circulating Tumor DNA Molecular Residual Disease Testing In The Clinical Practice Guidelines In Oncology For Colon Cancer, Rectal Cancer, And Merkel Cell Carcinoma

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 25.51% on an annualized basis producing an average annual return of 38.05%. Currently, Natera has a market capitalization of $23.14 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $495.06 today based on a price of $175.25 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738854910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today

WIIM

Natera shares are trading higher after the company announced it gained national commercial coverage for fetal RhD NIPT and is expanding its access to noninvasive prenatal testing.

Coverage from one of the largest payors in the country expands access to fetal RhD testing for pregnant patients nationwide

Natera Gains National Commercial Coverage For Fetal RhD NIPT, Expanding Access To Noninvasive Prenatal Testing

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54197454&amp;newsitemid=20250203957122&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=57559066139c4e5dbfbbca31156a600f">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United States.
Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy.
Up to 15 percent of pregnant patients are RhD-negative1. When the maternal blood type is RhD-negative and the fetal blood type is RhD-positive, antibodies can develop (alloimmunization) that can lead to hemolytic disease of the fetus and newborn.
Natera's Fetal RhD NIPT can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient. It is offered through the Company's women's health suite of products, which includes Panorama, the no. 1 ordered NIPT in the U.S.

Natera Secures Insurance Coverage for Fetal RhD Noninvasive Prenatal Test, Expanding Access for High-Risk Pregnancies

Goldman Sachs analyst Matthew Sykes maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $160 to $190.

Price Target

Goldman Sachs Maintains Buy on Natera, Raises Price Target to $190

Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera&#x2122; positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone
Additional ASCO GI poster highlights data from the ALTAIR clinical trial, showing significant clinical benefit in patients with stage IV colorectal cancer who were treated with Trifluridine/Tipiracil (FTD/TPI)

Reported Saturday, Natera Reports Results From Phase III CALGB (Alliance) / SWOG 80702 Randomized Clinical Trial In Colorectal Cancer

Barclays analyst Luke Sergott initiates coverage on Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight rating and announces Price Target of $200.

Initiation

Barclays Initiates Coverage On Natera with Overweight Rating, Announces Price Target of $200

Natera shares are trading higher after the company announced it will reveal new insights and innovations for tissue-free MRD at ASCO GI 2025

<ul>
<li>First set of abstracts released include Signatera&#x2122; data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early cancer detection and tissue-free MRD</li>
<li>Additional Signatera data will be shared at ASCO GI on Jan. 25, 2025, including a late-breaking oral presentation on the CALGB (Alliance) / SWOG 80702 study</li>
</ul>

Reported Earlier, Natera To Reveal New Insights On Signatera's Clinical Utility And Innovations In Tissue-Free MRD At ASCO GI 2025

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has risen 6.87% since its last report. The company recently reported that it has 4.32 million shares sold short, which is 3.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737382517_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 5.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

Looking Into Natera's Recent Short Interest

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">initiated a short position in the company</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">analyst estimates of $2.951 billion</a>. Morgan Stanley maintained an Equal-Weight rating and lowered the <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $70 to $38</a>.</li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">steered investors toward</a> quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is<a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener"> successfully operating in orbit</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) stock lost 9.51% last week despite Guggenheim <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast</a> from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock decreased 9.27%  after the company issued FY24 revenue guidance <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">below the previous estimate</a>.</li>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) stock fell 9.22% after the company issued FY25 guidance with <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">its midpoint below estimates</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares declined 8.89% after Moderna issued 2025 revenue <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">guidance below analyst estimates</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">Medicare drug price negotiations</a>.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">Unified Patent Court (UPC) in Munich, Germany</a>.</li>
</ol>
Photos courtesy: Shutterstock

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="586" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--1024x586.jpg" alt="" class="wp-image-4711" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--1024x586.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--300x172.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--768x440.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40-.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The End Of The 60/40 Portfolio&nbsp;</h2>
For years, a common investing approach was the 60/40 portfolio: 60% in stocks, and 40% in bonds. The idea behind it was simple: bonds were expected to outperform when stocks underperformed, and vice-versa. But as Tatiana Darie of Bloomberg pointed out yesterday (&#8220;<a href="https://www.zerohedge.com/markets/shifting-correlations-unleash-market-havoc" target="_blank" rel="noreferrer noopener nofollow">Shifting Correlations Unleash Market Havoc</a>&#8220;), that is no longer the case:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">Whether&nbsp;good&nbsp;or bad, shifting correlations are poised to wreak havoc on cross-asset strategies, and hedging assumptions will likely need to change. In the current environment, bonds are no longer proving to be a shield from stock losses.&nbsp;Jim Bianco&nbsp;of Bianco Research says the reason to hold bonds is changing, calling the days of the 60/40 portfolio&nbsp;"over."
It also means that trading might require a more creative and active approach that goes beyond traditional (and stale) assumptions.
</blockquote>
<h2 class="wp-block-heading">Moving Beyond Traditional (And Stale) Assumptions</h2>
As it happens, we developed an approach that moves beyond traditional assumptions. Specifically, it moves beyond the assumption that asset allocation is useful at all. The 60/40 portfolio, and other forms of asset allocation, deliberately put you in asset classes expected to perform badly. Why not put your money in assets you expect will do well? If you&#8217;re worried about downside risk, you can hedge with options. That&#8217;s essentially our approach, <a href="https://portfolioarmor.com/" target="_blank" rel="noreferrer noopener nofollow">The Hedged Portfolio Method</a>. 
<h2 class="wp-block-heading">The Hedged Portfolio Method&nbsp;</h2>
Here&#8217;s how our method works, in a nutshell:&nbsp;
<ol>
<li>Our system estimates 6-month returns for each security with options traded on it in the U.S. In addition to stocks, this universe of securities includes bond and commodity ETFs and even inverse ETFs. Our system is completely agnostic when it comes to asset class.&nbsp;</li>
<li>Next, our system finds optimal hedges for each security, and calculates their cost.&nbsp;</li>
<li>We subtract the hedging costs in 2. from the estimated returns in 1. and rank the securities by expected return, net of hedging cost.&nbsp;</li>
<li>The names that come to the top of the list in 3. are our top names. We buy and hedge a handful of them.&nbsp;</li>
</ol>
There are some additional steps, such as using a tightly collared &#8220;cash substitute&#8221; to minimize cash and boost returns, but that&#8217;s the gist of it.&nbsp;
<h2 class="wp-block-heading">Precisely Limiting Your Risk</h2>
One advantage of our approach is that you can precisely limit your risk. Don&#8217;t want to risk a decline of more than 17% over the next 6 months? Our system will hedge it so you don&#8217;t. Much different from putting 40% of your money in bonds and hoping for the best.&nbsp;
<h2 class="wp-block-heading">A Real World Example&nbsp;</h2>
Here&#8217;s a portfolio our system created for an investor in July of last year. This was for an investor unwilling to risk a decline of more than 20% over the next 6 months. This one included&nbsp;American Superconductor Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>),&nbsp;Abercrombie &amp; Fitch Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>),&nbsp;Constellation Energy Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>),&nbsp;Dell Technologies, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>),&nbsp;Navios Maritime Partners LP&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMM#NYSE">NMM</a>),&nbsp;Natera, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), and&nbsp;Powell Industries, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>).
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="776" height="717" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio.jpg" alt="" class="wp-image-4712" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio.jpg 776w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio-300x277.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio-768x710.jpg 768w" sizes="(max-width: 776px) 100vw, 776px" /></figure>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="778" height="598" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio.jpg" alt="" class="wp-image-4713" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio.jpg 778w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio-300x231.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio-768x590.jpg 768w" sizes="(max-width: 778px) 100vw, 778px" /></figure>
Here is how that portfolio performed over the next six months:&nbsp;
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="800" height="623" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1.jpg" alt="" class="wp-image-4714" style="width:800px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1.jpg 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1-300x234.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1-768x598.jpg 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="800" height="319" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2.jpg" alt="" class="wp-image-4715" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2.jpg 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2-300x120.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2-768x306.jpg 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
You can find an interactive version of that chart&nbsp;<a href="https://portfolioarmor.com/front_tests/5837">here</a>. And you can see how hundreds of other hedged portfolios have done&nbsp;<a href="https://portfolioarmor.com/performance-tracking-portfolios">here</a>.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and create hedged portfolios on <a href="https://portfolioarmor.com/" target="_blank" rel="noreferrer noopener nofollow">our website</a>. You can also follow Portfolio Armor on X <a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to <a href="https://portfolioarmor.substack.com/">our trading Substack</a> using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085726/Widget-5.jpg" alt="" class="wp-image-4716" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085726/Widget-5.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085726/Widget-5-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) from $108 to $124. JP Morgan analyst Kian Abouhossein maintained a Neutral rating. Morgan Stanley shares closed at $135.81 on Thursday. <a href="https://www.benzinga.com/quote/MS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group slashed Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) price target from $53 to $51. Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating. Bank of America shares closed at $46.64 on Thursday. <a href="https://www.benzinga.com/quote/BAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised the price target for Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) from $25 to $30. Barrington Research analyst Alexander Paris maintained an Outperform rating. Universal Technical Institute shares closed at $26.00 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim increased the price target for Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) from $170 to $200. Guggenheim analyst Subbu Nambi maintained a Buy rating. Natera shares closed at $168.50 on Thursday. <a href="https://www.benzinga.com/quote/NTRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) price target from $208 to $200. Wells Fargo analyst Joe Quatrochi maintained an Equal-Weight rating. Texas Instruments shares settled at $187.37 on Thursday. <a href="https://www.benzinga.com/quote/TXN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) price target from $35 to $41. Northland Capital Markets analyst Michael Latimore maintained an Outperform rating. Symbotic shares closed at $31.82 on Thursday. <a href="https://www.benzinga.com/quote/SYM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays increased NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) price target from $160 to $175. Barclays analyst Blayne Curtis maintained an Overweight rating. Nvidia shares closed at $133.57 on Thursday.  <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from $23 to $30. Piper Sandler analyst David Amsellem maintained an Overweight rating. Teva Pharmaceutical shares settled at $21.68 on Thursday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Planet Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) price target from $90 to $100. JP Morgan analyst Rahul Krotthapalli maintained an Overweight rating. Planet Fitness shares closed at $105.98 on Thursday. <a href="https://www.benzinga.com/quote/PLNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods cut KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) price target from $85 to $76. Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained a Market Perform rating. KB Home shares closed at $68.25 on Thursday. <a href="https://www.benzinga.com/quote/KBH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43049593/slb-jb-hunt-transport-and-3-stocks-to-watch-heading-into-friday">SLB, J.B. Hunt Transport And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

PLNT

Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $170 to $200.

Guggenheim Maintains Buy on Natera, Raises Price Target to $200

Events

Natera To Provide Roadmap And Outlook At  J.P. Morgan Healthcare Conference

Natera shares are trading higher after the company reported preliminary FY24 financial results.

Press Releases

Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Natera to Present New Data at the 2025 ASCO GI Symposium

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Comments

Natera

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga